HEAD AND NECK SQUAMOUS CELL CANCER
Clinical trials for HEAD AND NECK SQUAMOUS CELL CANCER explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CANCER trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug XB010 shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. About 396 adults with cancers…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New injection combo shows promise against head and neck cancer
Disease control Recruiting nowThis early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: VLP Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug EPI-326 enters human testing for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Smart CAR t cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC